A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia.

Shimeng DongJohannes Schneider-ThomaIrene BighelliSpyridon SiafisDongfang WangAngelika BurschinskiKristina SchestagMyrto SamaraStefan Leucht

Published in: European archives of psychiatry and clinical neuroscience (2023)

Clozapine remains the gold standard for patients with treatment-resistant schizophrenia. Olanzapine seems to be second-best and could be tried before switching to clozapine.

Keyphrases

bipolar disorder
open label
clinical trial
randomized controlled trial
silver nanoparticles